Outpatient high-dose chemotherapy and autologous stem cell transplantation (ASCT) has been shown to be feasible in terms of physical morbidity and mortality outcomes, but few data exist on the psychosocial impact of delivering such aggressive therapy in this manner. The purpose of this observational study was to compare effects of inpatient (n = 20) and outpatient (n = 21) modes of care on physical status, psychological wellbeing, quality of life, personal finances and caregiver burden. Most patients were treated according to their preference for inpatient or outpatient care. Those choosing outpatient care were screened for eligibility according to established criteria for ambulatory management. Measures were taken at baseline, then at days 4-6, 12-16 and 30 post ASCT. Results showed that overall, the psychological, physical, social and financial outcomes of the outpatient ASCT group were comparable, to or better than inpatients. Factors that seem to be important for successful outpatient management are previous experience with cancer treatment, a satisfying quality of life, physical well-being, patient's preference for a particular mode of care and physical proximity to the treatment centre. The study results suggest that outpatient ASCT is an efficient, effective and acceptable form of care for motivated patients and caregivers who have the physical and psychological capability and desire to receive cancer treatment in this manner. Bone Marrow Transplantation (2000) 26, 389-395.
However, there is no empirical evidence to indicate that this approach is appropriate, affordable and acceptable.
The purpose of this observational study was to explore differences between inpatients and outpatients receiving HDCT/ASCT with respect to physical status, psychological well-being, quality of life, caregiver burden, inpatient bed utilization and personal financial impact. Understanding the type of patients who may choose outpatient care and the impact of receiving such care may help clinicians in identifying appropriate support for this type of care.
Patients and methods

Study design and patients
This was an observational study requesting all cancer patients who were referred to the cancer centres for HDCT/ASCT to participate. All patients but one accepted. Enrollment continued for 7 months until a sample of 41 had been achieved: 20 for inpatient care and 21 for outpatient care. The study was conducted in Alberta Canada, at the Tom Baker Cancer Centre/Foothills Medical Centre, Calgary and the Cross Cancer Institute, Edmonton from April to October 1997. At the time, outpatient care was just beginning at the cancer centres and no formal outcome evaluation had been done. In this study, cancer patients were not randomized to either form of care, but rather they received care according to their preference. Requirements for those who preferred the outpatient model included absence of significant morbidity, travel time to hospital of 45 min or less, and the availability of a caregiver 24 h per day.
Methods
Following transplantation, inpatients were cared for in private rooms in an acute care hospital attached to the cancer treatment center. Protective isolation procedures are not routinely used. All pre-and post-transplant procedures and care were provided in the hospital. Outpatients received care at a specialized ambulatory clinic at the cancer center. After each clinic visit local patients returned home, and outof-town patients returned to their temporary accommodation such as the home of a friend or relative, a hotel or apartment. There was no overnight facility staffed by nurses available for use by outpatients. During HDCT infusions, outpatients had their chemotherapy started at the clinic and then went home with an Abbott home infusion pump (Abbott Laboratories, Morgan Hill, CA, USA) running overnight. The various HDCT agents are listed in Table 1 . After completion of the HDCT, outpatients had stem cell infusions, blood transfusions, intravenous therapy for hydration, analgesics, and anti-nauseants administered at the clinic. The outpatient clinic closed each afternoon around 1500 h; patients were instructed to call the inpatient transplant ward if they had any questions or problems after hours. Criteria for admission for inpatient care were very flexible. Outpatients could be admitted for febrile neutropenia (temperature greater than 38.5°C) or any other serious complication (Bearman, grade 3 RRT), 5 need for intravenous narcotics for managing mucositis pain, and patient's or family's inability to cope at home. Inpatients and outpatients received the same supportive care in terms of prophylactic oral antibiotics, transfusion thresholds, posttransplant G-CSF injections, and dietary recommendations. As expected, methods for pain management differed between the groups; outpatients were more likely to use Fentanyl patches (Janssen-Ortho, North York, ON, Canada) while inpatients used both intravenous and oral analgesics.
Measurement
Measurement occurred at 4 time periods: 3-7 days prior to ASCT (baseline); and post treatment at days 4-6, 12-16 and 30. A limited number of measures were performed at day 30 because the majority of inpatients had been discharged from the acute care setting by this point in time. Also, this study required the patients and their families to complete a fairly large number of forms, and, to limit the burden of completing these forms, day 30 measures were kept to a minimum. Most measurement was done using standardized tools. Interpretation of scores from all the tools was the same: the higher the score, the greater the attribute being measured, with the exception of 'additional bone marrow transplant concerns' in the FACT-BMT, as noted in the following description of the measurement tools. Table 1 Types of cancer and treatments Breast cancer  15  71  5  24  Lymphoma  1  5  10  24  Hodgkin's disease  1  5  3  14  Multiple myeloma  2  10  1  5  Oligodendroglioma  1  5  0  Amyloidosis  0  1  5  Neuroblastoma  0  1  5  Treatment protocol  Mitoxantrone, Vinblastine,  13  65  4  19  Cyclophosphamide  Melphalan  3  15  16  76  Melphalan,  2  10  1  5  Total body irradiation  Mitoxantrone, Carboplatin,  1  5  0  Cyclophosphamide  Thiotepa  1  5  0 The Karnofsky Performance Scale (KPS) is a standard measure of physical performance, dependency and morbidity. 6 The scale measures the extent to which illness has disrupted an individual's normal activity pattern. Scores can range from 100% (no evidence of disease) to 0% (death). Karnofsky scores were assigned by the medical and nursing staff at the clinic. Patients with a KPS score below 70% were classified as having high morbidity. At this level individuals require assistance with caring for their own needs or require special medical care including hospitalization.
A measure of global quality of life (QOL) was generated by the self-administered Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT). 7 The tool is composed of a general QOL component (the FACT) and a component specific to bone marrow transplantation (the BMT). The QOL score is the sum of 38 items contained in the five subscales of physical, social, emotional and functional well-being, relationship with doctor, and additional bone marrow transplant concerns. The highest possible global QOL score is 152. The maximum score of 40 for additional bone marrow transplant concerns indicates minimum concern and thereby contributes to a high global quality of life score being interpreted as good quality of life.
A subscale of the FACT-BMT and two subscales of the shortened version of the Profile of Mood States Measure of Distress Scale (POMS) provided measures of emotional health, anxiety and depression, respectively. The short version of the POMS measures general psychological distress in cancer patients. Scales were self-administered and the maximum score on each of the three subscales was 20.
Perception of control and control over medical treatment were measured with the Perception of Control Instrument (PCI). 8 The tool is interviewer administered and evaluates cancer patients' perception of control in low control circumstances. The 13 items yield a maximum score of 56 for perception of control and two items gave a maximum score of 14 for control over medical treatment.
Caregivers completed the Caregiver Reaction Assessment (CRA) 9 and the Centre of Epidemiological StudiesDepression Scale (CES-D). 10 The CRA does not provide a global score of burden, rather each of the aspects of caregiver burden (24 items) are scored separately (esteem, impact on schedule, family support and impact on health and finances). Maximum scores on each of the components vary; the maximum score for esteem is 35. Caregivers' feelings of depression were measured by the CES-D. This 20-item screening tool is appropriate for a non-psychiatric population. Scores range from 0 to 60; the presence of depression is indicated by scores of 16 and over.
Patient satisfaction with care and financial impact were measured with tools developed for this study. Satisfaction questions focused on access to care, adequacy of education/information provided, adequacy of emotional and instrumental support, and overall satisfaction. A standard expense diary was kept by all patient and caregiver dyads. Out-of-pocket expenses for accommodation, transportation, domestic help, child care, medication and supplies, and special equipment were recorded.
Statistics
Exploratory and descriptive statistical methods appropriate for small sample sizes were used. Box plots illustrated the data distribution for each outcome variable. Depending on the distribution of the data, mean or median scores and 95% confidence intervals were calculated when the box plots suggested differences between inpatient and outpatient groups. When confidence intervals indicated a difference between groups, probability estimates for the difference were calculated. Confidence intervals were not calculated when the median scores as shown by the box plots suggested the groups were not different.
Results
Characteristics of patients and caregivers
Personal characteristics of the patients and caregivers are described in Table 2 . Most patients in either group were female. Inpatients and their caregivers were slightly older than the outpatient dyads, although overall, both groups were comparatively young. Inpatients and outpatients were similar with respect to most characteristics with two exceptions. Although not statistically significant, inpatients more than outpatients tended to be from communities at a distance from the cancer treatment center (60% vs 43%, P = 0.35). Second, outpatient caregivers were more likely to have previously cared for someone with a serious illness (17% vs 37%, P = 0.05). Outpatients did not identify caregiver's previous experience as a reason for preferring out of hospital care.
Types of cancer and treatments
As shown in Table 1 , there were differences between inpatients and outpatients with respect to types of cancer, chemotherapy protocols and experience with previous cancer treatment. Patients who had experience with cancer treatment were identified as those who had relapse of dis- Table 2 Characteristics of inpatient and outpatient groups
Characteristics Inpatients Outpatients
17 (85) Bone Marrow Transplantation ease or failed to respond to conventional chemotherapy. The majority of inpatients had breast cancer, while lymphoma, Hodgkin's disease and breast cancer were most common among outpatients. Accordingly, drug treatment protocols also differed between groups. The most frequently used treatment among inpatients was mitoxantrone, vinblastine and cyclophosphamide (65%). High-dose melphalan was used most often among outpatients (76%). The majority of outpatients (71%) had experienced treatment failure with previous cancer therapy, meaning that they had failed to respond to chemotherapy treatment. This higher proportion is accounted for by the high number of lymphoma patients, where all 10 cases were refractory. Treatment failure was less common among inpatients (35%, P = 0.02).
Physical status
There was no significant morbidity in either comparison group at baseline: no patients had a Karnofsky score less than 70%. Post ASCT, there was evidence of significant morbidity in both groups. At day 4-6, 78% of inpatients and 37% of outpatients had a KPS less than 70% (P = 0.01). By day 12-16, only 24% of inpatients were experiencing high morbidity but the proportion among outpatients had increased to 53%. Overall, none of the 41 patients experienced treatment-related mortality or severe toxicity requiring life-sustaining therapy. Table 3 shows that each group experienced moderate to severe side-effects, namely, fever, mouth sores, nausea, vomiting and diarrhea. The side-effects were considered to be clinically significant meaning that medical intervention was required. Fever was more prevalent among inpatients (95%) than outpatients (67%) (P = 0.02). Nausea and vomiting were slightly more frequent among outpatients with one-third of the group being admitted to hospital for management of these problems. Inpatients and outpatients rated nausea and mouth sores as the two most bothersome treatment side-effects. The main reason for hospital admission among outpatients was for intravenous therapy to treat Table 3 Occurrence of significant toxicities fever, mouth sores and dehydration: 52% of outpatients were admitted to hospital around day 6-7 often at the request of the patient or family (63%). Even though almost all outpatients were admitted to hospital sometime during the post-transplant period (19/21), the total time spent in hospital was significantly less compared with inpatients. The median number of nights spent in hospital by outpatients was seven (95% CI = 5-11 nights, range 0-15) compared with 14 nights for inpatients (95% CI = 13-17 nights, range 13-25) (P Ͻ 0.001).
Psychological well-being
Even though emotional well-being was high in both groups prior to transplantation and at each of the three post-treatment measurement intervals, outpatients registered better emotional well-being at each measurement interval compared with inpatients (see Table 4 ). The analysis was repeated, controlling for the effects of being in one's own home during the recovery period, and experience with previous cancer treatment. Outpatients who were able to remain in their own home with their own families scored higher on emotional well-being at all three time intervals compared with inpatients whose families had not relocated for the duration of their cancer treatment. The difference was evident in the early post-transplant period (day 4-6) and by day 12-16 when treatment side-effects from all protocols had subsided, outpatients in their own home were doing better than comparable inpatients (median scores 13 vs 18, P Ͻ 0.001) and the effect was still evident at day 30 (median scores 15 vs 19, P = 0.01).
With respect to experience with previous cancer treatment, the subgroup of outpatients with this experience rated higher on emotional well-being compared to the corresponding group of inpatients. At day 4-6 the difference was statistically significant (scores of 12 vs 16, P = 0.005). A differential was evident until day 30.
Patients' feelings of anxiety and depression were measured prior to and following transplant. For both anxiety and depression, high scores up to 20 indicated psychological distress. Anxiety and depression were low at all time intervals and there were no differences between comparison groups. However, results show that outpatients with high morbidity were more likely to be anxious (11, 95% CI = 2-14) compared to inpatients (6, 95% CI = 4-9). The same effect was evident for outpatients with no previous experience with cancer treatment; 8.5 (95% CI = 1-14) and 5 (95% CI = 4-8).
Patients in both study groups perceived a high level of control particularly with respect to control over their medical treatment. There were no significant differences in the median scores between the groups at baseline or any of the time intervals after the transplant. Although at day 12-16 it seems that outpatients' perception of control over medical care may have been somewhat higher than inpatients' (12; 95% CI = 10-14 and 9.5; 95% CI = 7.5-13, respectively) (P = 0.06).
Prior to the transplant, inpatients reported significantly more concern about the transplant affecting their general health compared to outpatients; 26.5 (95% CI = 24-29) and 31 (95% CI = 28-34) (P = 0.04). At day 4-6, patients in both study groups showed more concern about their health than was evident on the baseline measure. Concern diminished somewhat over time, but never returned to the baseline level. The amount of concern expressed by both groups was similar, and overall patients did not express excessive concern at any of the time intervals. Since more outpatients had experienced previous cancer treatment, the effects of this factor on general health concerns were explored. At day 4-6, outpatients who had prior cancer treatment reported less concern about their health (median score = 21; 95% CI = 20-26) compared with equivalent inpatients (median score = 17; 95% CI = 16-19) (P = 0.02). At day 12-16, concern among inpatients remained higher. However, the difference between the groups was not significant.
Global quality of life
Prior to transplant, the global quality of life for both groups was relatively high. However outpatients gave significantly higher ratings by 12%, compared with inpatients (122; 95% CI = 112-132 vs 104; 95% CI = 94-114) (P = 0.04). There were no differences between the groups at any of the time intervals after transplant, and for both groups QOL was rated lowest at day 4-6 (inpatients 77 vs outpatients 81), with improvements at day 12-16 (89 vs 81). Despite the gains made over time, pretreatment QOL had not been achieved by day 30 for either group.
The analysis was repeated to observe the effects of experience with previous cancer treatment. Outpatients with previous cancer treatment reported higher quality of life prior to transplant and at all three time intervals following transplant compared with their inpatient counterparts. Because of the small sample size, comparisons at the three time intervals were not shown to be significantly different.
Caregiver well-being
An understanding of caregivers' emotional well-being was obtained from measures of depression and anxiety using the CES-D and POMS scales. Scores showed that 39% (95% CI = 17 to 62%) of inpatient caregivers and 28% (95% CI = 7-49%) of outpatient caregivers were experiencing some degree of depression at day 4-6. However, median scores (14 and 11, respectively) indicate that overall the groups were not characterized as depressed (defined as scores greater than 16) and the difference was not statistically significant. By day 12-16 scores for both groups were 12. Feelings of anxiety as measured by the POMS, were low for both groups at all time intervals. At day 4-6, scores were 6 and 5 for inpatient and outpatient caregivers, respectively, and at day 12-16 there was no change.
Burden, as indicated by impact on schedule, was evident for caregivers of inpatients and outpatients. At each measurement interval following ASCT, caregivers in the two groups had similar scores on the Caregiver Reaction Assessment scale. Scores for each group ranged from 15 to 18 at each of the time intervals. Relocation for the duration of treatment appeared to influence caregivers' schedules. When considering only those who were from out-of-town, results showed that caregivers of outpatients may have experienced a greater impact on their schedules on day 4-6 (18; 95% CI = 16-21) compared to equivalent inpatient caregivers (13; 95% CI = 12-22). By day 12-16 scores were similar (16 and 17).
It was possible that employment responsibilities could affect caregiver's schedules. The experience of the study sample was that 39 and 33% of outpatient and inpatient caregivers, respectively, changed their employment status. Changes included reducing hours, for example from fulltime to part-time work, leave of absence and resignation. For caregivers who remained employed either full time or part time, impact scores were in a range similar to that of the entire sample, and scores did not differ between comparison groups. Finally, caregiver's schedules did not seem to be affected by the level of morbidity experienced by the patient.
Burden, as indicated by caregiver esteem, was also similar between groups. Scores at day 4-6 were 31 for inpatients and 29 for outpatients; days 12-16 and 30 were in the same range. There were no differences between groups according to gender but previous experience of providing care to someone with a serious illness influenced esteem. At day 4-6, outpatient caregivers with no previous experience in a caring role reported slightly lower levels of caregiver esteem (28.5; 95% CI = 26-31) compared to inpatient caregivers (31; 95% CI = 29-31) (P = 0.06). At days 12-16 and 30, scores for both groups were similarly high in the range of 28 to 30. Finally, the effect of caregiver anxiety and depression on esteem could not be determined due to an insufficient sample size.
Measures of caregiver burden, as indicated by impact of caring on health and adequacy of family support, indicated that neither inpatient nor outpatient caregivers experienced a decline in their own health and that both groups received sufficient family support. Impact on health was not influenced by the patient's level of morbidity. The sample was insufficient for examining the effect of caregiver age on health.
Financial impact
All inpatient and ambulatory services required by inpatients and outpatients were insured under the Canadian national health insurance program. In order to estimate the out-ofpocket expenses incurred, patients and caregivers were asked to record specific types of expenses during the 30-day study period, starting the day of the transplant. Expenses included travel, parking, lodging, prescription medication, child care and telephone and television rental. The largest expenses for both groups were for travel, medication and parking. However, the majority (78%) of patients had additional insurance coverage that provided reimbursement for the costs of medications. Total out-of-pocket expenses incurred during the 30-day period following ASCT was about the same for inpatients and outpatients (average of $340 and $380, respectively). There was wide variation in expenses depending on the needs of the patient and family. The lowest expenses recorded for inpatients were $130 and $70 for outpatients while the highest expenses were $1570 and $1010, respectively. Only three inpatients and two outpatients (all from communities outside the treatment centres) reported expenses in excess of $1000. Higher expenses were attributable to costs of preferred hotel accommodation and travel to and from their home community. Although expenses were not excessive overall, both study groups identified personal finances as a concern.
Indirect expenses such as caregiver's loss of salary and loss of employer payments to a health plan and pension were identified during the 30-day time period. Two caregivers from the inpatient group and one from the outpatient group experienced loss of the employer's contribution to cost of health care benefits. Loss of salary was experienced by four caregivers in the inpatient group and two caregivers in the outpatient group.
Patient preference for inpatient or outpatient care
Most patients received the type of care they preferred. Of the 41 subjects in the study, initially 46% preferred inpatient care and 90% of them actually received this mode of care. Of the 49% who preferred outpatient care, 86% were treated this way. Thirty days after transplant, both groups were again asked about their preference. Inpatients were more likely to prefer the care they received compared with outpatients (89% vs 53%, P = 0.02).
Reasons given by patients for preferring in-hospital care included: belief that hospital care is necessary; the hospital provides safety, a sense of security and ready access to care; the arrangements for outpatient care were not appropriate (need for frequent travel to hospital when feeling ill and uncomfortable physical set-up of the out-patient clinic);
and an anticipation that it would be difficult to rest at home since domestic obligations would be difficult to ignore. Reasons given for preferring ambulatory-based care were: home is a better environment for recuperation (more personal control, less focus on sickness) and more comfortable (quiet, familiar, unconfined, private, secure). Even though patients had specific views about the benefits and disadvantages of each type of care, a high level of satisfaction with care was reported.
Discussion
The results from this study are consistent with conclusions from other research that outpatient-based ASCT is an appropriate and acceptable service delivery model for selected patients. The main findings of this study suggest that ambulatory care, when compared with inpatient care, does not appear to have a significant negative impact on physical health and psychological well-being during a 30-day period of recovery, or a differential impact on out-of-pocket expenses. Patients in our study selected the mode of care right for them and their own circumstances. This flexibility may account for the relatively uneventful and similar recovery experiences of inpatients and outpatients.
The study results showed that inpatients experienced a higher level of morbidity at day 4-6 post transplant compared with outpatients. This was likely to be attributable to different cancer diagnoses and drug treatment protocols within each group rather than differences in the mode of care. The most frequently used treatment protocol among inpatients was mitoxantrone, vinblastine and cyclophosphamide (65%). This reflects the high proportion of breast cancers among inpatients. Side-effects with the protocol are at their worst 2-4 days after treatment. In comparison, highdose melphalan was used most often among outpatients (76%), which reflects the high proportion of lymphomas in the group. The side-effects with this treatment protocol are at their worst around day 6-7. Therefore, the day 4-6 measures of physical performance reflect a 'morbid' period for inpatients, when side-effects may still be present although beginning to resolve. In contrast, outpatients at day 4-6 are in a 'pre-morbid' state where side-effects have not yet started and physical performance is not yet affected.
Different drug treatment protocols may also account for a significantly higher incidence of fever among inpatients (95%) compared with outpatients (67%). Patients treated with mitoxantrone, vinblastine and cyclophosphamide (the majority of inpatients) experienced a longer period of neutropenia and thus were more likely to be febrile.
In this study 90% (n = 19) of outpatients were admitted to the hospital at some time during the 30-day posttreatment period. Most (52%) were admitted around posttreatment day 6-7 when side-effects were at their worst. Complaints included fever, mouth sores, nausea and vomiting. Lawrence et al 11 also found an increased incidence of nausea and vomiting among outpatients in their study. These researchers concluded that nausea and vomiting are better managed by nurses in a hospital setting than by patients and caregivers at home. Although outpatients in this study were admitted to hospital when necessary, hospital utilization was significantly lower compared with inpatients. This finding has implications for inpatient bed utilization and costs.
A large proportion of outpatients' admissions (63%) to hospital were in response to requests from patients and/or caregivers for assistance with managing treatment-related illness. In light of the evidence that outpatients and caregivers have substantial care needs, often met through hospital admission, it seems that care protocols for outpatient ASCT should include specific and effective support and interventions for managing side-effects at home. Despite the struggles outpatients and caregivers had with managing side-effects of treatment, results showed that among outpatients who were able to remain in their own home during treatment and recovery, home-based care had a positive influence on emotional well-being.
The study also explored patients' anxiety and general concerns about the effects of undergoing ASCT on their health. During the early period after HDCT when patients were experiencing side-effects and treatment-related morbidity was at its highest, both groups expressed more concern about their health. Concern was not accompanied by anxiety among inpatients perhaps because of the immediate accessibility to professional care. In contrast, outpatients were both concerned and anxious perhaps because of the burden of managing at home with less readily accessible professional support and care.
The experience of having had previous cancer treatment was positively associated with quality of life. Outpatients were more likely to have a higher quality of life at the beginning of treatment, and they were also more likely to have had previous cancer treatment. A possible explanation for these associations is that people with previous cancer treatment experience know what to expect and this somehow sustains their overall sense of quality of life, particularly if the experience was not remembered as highly negative, for example, painful or with many unpleasant side-effects. They anticipate their next experience with HDCT will be similar and therefore believe they could manage well with outpatient care.
McCorkle and colleagues 12 reported that high levels of patient morbidity or symptom distress were associated with an increased burden on the caregiver. We did not see the same effect in our study. Our results show that the greatest impact on the caregiver was related to alterations in their routine. Caregivers' schedules were affected regardless of whether the patient was cared for in hospital or at home. The impact was particularly evident for outpatient caregivers who were from out-of-town and living under temporary conditions away from family and community for the duration of post-transplant recovery. Caregivers who were employed also seemed to bear a greater burden. In our sample, 84% of outpatient caregivers were employed when treatment started; of these, 39% experienced a change in their employment status to accommodate their care-taking responsibilities. Programs developed for outpatient ASCT should acknowledge this burden and, whenever possible, advocate on behalf of the patient and family for compassionate consideration from employers.
We also attempted to describe and quantify the personal day-to-day expenses that occur for everyone and are typ-ically paid for out-of-pocket. Outpatients and their caregivers were not burdened excessively with these types of expenses. Furthermore, the costs incurred by inpatients and outpatients were similarly low. All health services provided to people in our sample were insured under a single public health insurance program. There were no direct charges to patients. Given the variety of insurance and payment options elsewhere, the results from this study regarding outof-pocket expenses are applicable for treatment programs whose patients are similarly insured. Indirect expenses were experienced by a small proportion of caregivers and were found to be similar in frequency between the two study groups. Since the amount of money attributable to indirect expenses was so variable because of differences in employment situations and pay, specific comparisons between the two study groups were not meaningful and therefore not pursued.
Interpretation of the study results is obscured to some extent because of the self-selected nature of the participants. That is, subjects were not assigned to a particular form of care. Instead they received services according to their preference for either inpatient or outpatient care. Baseline measures showed that inpatients and outpatients differed in a number of characteristics. Thus, results showing differences between groups may be accounted for by non-equivalence of the comparison groups rather than the form of care given (inpatient or outpatient). Despite this limitation, it should be noted that the study was not undertaken as a randomized trial, but rather as an observational and descriptive study. The results are helpful for understanding which patients might choose or are best suited for inpatient and outpatient care, and for understanding the impact of the two different forms of care on various aspects of health and well-being.
This study used a wide range of measures to describe and compare the physical and psychological well-being of inpatients and outpatients recovering from stem cell transplantation. Differences between groups were not always shown to be statistically significant. We attribute this to a lack of power stemming from a small sample size. However, when the results are taken in their entirety, we found consistently that outpatients fared better than inpatients on all measures of physical and psychological well-being.
In conclusion, outpatient treatment was well tolerated if the patient initially preferred outpatient care, and then remained relatively well during the recovery period following HDCT. People who chose outpatient care were characterized as having past experience with cancer treatment, a satisfying quality of life and sense of physical well-being, and lived in close proximity to a treatment centre. Enthusiasm for outpatient ASCT, however, should be tempered by Bone Marrow Transplantation the realisation that some patients may not have the desire or caregiver support to undergo ASCT successfully in this manner. These factors should be considered when screening patients and families for outpatient ASCT.
